(INGN) Inogen - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45780L1044
Stock: Portable Oxygen Concentrators, Accessories, Batteries, Rented Equipment
Total Rating 18
Risk 48
Buy Signal -0.42
| Risk 5d forecast | |
|---|---|
| Volatility | 54.6% |
| Relative Tail Risk | -16.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.33 |
| Alpha | -44.74 |
| Character TTM | |
|---|---|
| Beta | 1.247 |
| Beta Downside | 0.038 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.89% |
| CAGR/Max DD | -0.34 |
EPS (Earnings per Share)
Revenue
Description: INGN Inogen February 28, 2026
Inogen, Inc. (NASDAQ: INGN) designs, manufactures, and markets portable and stationary oxygen-concentrator systems for patients with chronic respiratory diseases, offering both sales and direct-to-patient rental models across the United States and select international markets.
For the fiscal year ended December 2025, Inogen reported revenue of $254 million, a 12% year-over-year increase driven primarily by a 15% rise in unit shipments of its flagship Inogen One and Rove devices. Rental contracts now represent roughly 42% of total revenue, and operating cash flow turned positive at $21 million, supporting ongoing R&D investment in next-generation concentrator technology.
Sector-wide, the home-based oxygen market is expanding as the U.S. population ages-people 65 and older are projected to reach 78 million by 2030, boosting prevalence of COPD and other chronic lung conditions. Additionally, Medicare’s enhanced reimbursement for home oxygen therapy and the lingering demand for portable respiratory support post-COVID-19 are key economic drivers supporting Inogen’s growth outlook.
For a deeper, data-rich analysis of Inogen’s valuation, you may want to explore ValueRay’s research platform.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -22.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA -3.35 > 1.0 |
| NWC/Revenue: 38.65% < 20% (prev 32.40%; Δ 6.25% < -1%) |
| CFO/TA -0.04 > 3% & CFO -11.2m > Net Income -22.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.2m) vs 12m ago 14.89% < -2% |
| Gross Margin: 47.58% > 18% (prev 0.46%; Δ 4712 % > 0.5%) |
| Asset Turnover: 117.2% > 50% (prev 113.3%; Δ 3.89% > 0%) |
| Interest Coverage Ratio: -17.88 > 6 (EBITDA TTM -4.11m / Interest Expense TTM -1.39m) |
Altman Z'' -1.21
| A: 0.45 (Total Current Assets 198.3m - Total Current Liabilities 63.5m) / Total Assets 298.6m |
| B: -0.59 (Retained Earnings -175.6m / Total Assets 298.6m) |
| C: -0.08 (EBIT TTM -24.8m / Avg Total Assets 297.4m) |
| D: -1.61 (Book Value of Equity -171.3m / Total Liabilities 106.4m) |
| Altman-Z'' Score: -1.21 = CCC |
Beneish M -2.88
| DSRI: 1.24 (Receivables 38.9m/30.1m, Revenue 348.7m/335.7m) |
| GMI: 0.97 (GM 47.58% / 46.09%) |
| AQI: 0.98 (AQ_t 0.16 / AQ_t-1 0.16) |
| SGI: 1.04 (Revenue 348.7m / 335.7m) |
| TATA: -0.04 (NI -22.7m - CFO -11.2m) / TA 298.6m) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of INGN shares?
As of March 05, 2026, the stock is trading at USD 6.31 with a total of 300,814 shares traded.
Over the past week, the price has changed by +4.99%, over one month by +8.05%, over three months by -9.73% and over the past year by -21.42%.
Over the past week, the price has changed by +4.99%, over one month by +8.05%, over three months by -9.73% and over the past year by -21.42%.
Is INGN a buy, sell or hold?
Inogen has received a consensus analysts rating of 3.67.
Therefor, it is recommend to hold INGN.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the INGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | 106% |
| Analysts Target Price | 13 | 106% |
INGN Fundamental Data Overview March 05, 2026
P/S = 0.4835
P/B = 0.8516
P/EG = 3.48
Revenue TTM = 348.7m USD
EBIT TTM = -24.8m USD
EBITDA TTM = -4.11m USD
Long Term Debt = 14.3m USD (estimated: total debt 17.5m - short term 3.16m)
Short Term Debt = 3.16m USD (from shortTermDebt, last quarter)
Debt = 17.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -86.3m USD (from netDebt column, last quarter)
Enterprise Value = 66.5m USD (168.6m + Debt 17.5m - CCE 119.6m)
Interest Coverage Ratio = -17.88 (Ebit TTM -24.8m / Interest Expense TTM -1.39m)
EV/FCF = -3.13x (Enterprise Value 66.5m / FCF TTM -21.3m)
FCF Yield = -31.98% (FCF TTM -21.3m / Enterprise Value 66.5m)
FCF Margin = -6.10% (FCF TTM -21.3m / Revenue TTM 348.7m)
Net Margin = -6.52% (Net Income TTM -22.7m / Revenue TTM 348.7m)
Gross Margin = 47.58% ((Revenue TTM 348.7m - Cost of Revenue TTM 182.8m) / Revenue TTM)
Gross Margin QoQ = 50.44% (prev 50.82%)
Tobins Q-Ratio = 0.22 (Enterprise Value 66.5m / Total Assets 298.6m)
Interest Expense / Debt = 10.08% (Interest Expense 1.76m / Debt 17.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -19.6m (EBIT -24.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.12 (Total Current Assets 198.3m / Total Current Liabilities 63.5m)
Debt / Equity = 0.09 (Debt 17.5m / totalStockholderEquity, last quarter 192.2m)
Debt / EBITDA = 21.01 (negative EBITDA) (Net Debt -86.3m / EBITDA -4.11m)
Debt / FCF = 4.06 (negative FCF - burning cash) (Net Debt -86.3m / FCF TTM -21.3m)
Total Stockholder Equity = 196.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.65% (Net Income -22.7m / Total Assets 298.6m)
RoE = -11.56% (Net Income TTM -22.7m / Total Stockholder Equity 196.7m)
RoCE = -11.74% (EBIT -24.8m / Capital Employed (Equity 196.7m + L.T.Debt 14.3m))
RoIC = -9.87% (negative operating profit) (NOPAT -19.6m / Invested Capital 198.2m)
WACC = 10.27% (E(168.6m)/V(186.1m) * Re(10.51%) + D(17.5m)/V(186.1m) * Rd(10.08%) * (1-Tc(0.21)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.97%
[DCF] Fair Price = unknown (Cash Flow -21.3m)
EPS Correlation: 42.25 | EPS CAGR: 18.05% | SUE: 0.73 | # QB: 0
Revenue Correlation: -13.36 | Revenue CAGR: 0.44% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.03 | Chg7d=-0.030 | Chg30d=-0.030 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.52 | Chg7d=-0.360 | Chg30d=-0.360 | Revisions Net=-1 | Growth EPS=-73.3% | Growth Revenue=+5.8%
EPS next Year (2027-12-31): EPS=-0.31 | Chg7d=-0.360 | Chg30d=-0.360 | Revisions Net=-1 | Growth EPS=+40.4% | Growth Revenue=+7.9%
P/B = 0.8516
P/EG = 3.48
Revenue TTM = 348.7m USD
EBIT TTM = -24.8m USD
EBITDA TTM = -4.11m USD
Long Term Debt = 14.3m USD (estimated: total debt 17.5m - short term 3.16m)
Short Term Debt = 3.16m USD (from shortTermDebt, last quarter)
Debt = 17.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -86.3m USD (from netDebt column, last quarter)
Enterprise Value = 66.5m USD (168.6m + Debt 17.5m - CCE 119.6m)
Interest Coverage Ratio = -17.88 (Ebit TTM -24.8m / Interest Expense TTM -1.39m)
EV/FCF = -3.13x (Enterprise Value 66.5m / FCF TTM -21.3m)
FCF Yield = -31.98% (FCF TTM -21.3m / Enterprise Value 66.5m)
FCF Margin = -6.10% (FCF TTM -21.3m / Revenue TTM 348.7m)
Net Margin = -6.52% (Net Income TTM -22.7m / Revenue TTM 348.7m)
Gross Margin = 47.58% ((Revenue TTM 348.7m - Cost of Revenue TTM 182.8m) / Revenue TTM)
Gross Margin QoQ = 50.44% (prev 50.82%)
Tobins Q-Ratio = 0.22 (Enterprise Value 66.5m / Total Assets 298.6m)
Interest Expense / Debt = 10.08% (Interest Expense 1.76m / Debt 17.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -19.6m (EBIT -24.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.12 (Total Current Assets 198.3m / Total Current Liabilities 63.5m)
Debt / Equity = 0.09 (Debt 17.5m / totalStockholderEquity, last quarter 192.2m)
Debt / EBITDA = 21.01 (negative EBITDA) (Net Debt -86.3m / EBITDA -4.11m)
Debt / FCF = 4.06 (negative FCF - burning cash) (Net Debt -86.3m / FCF TTM -21.3m)
Total Stockholder Equity = 196.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.65% (Net Income -22.7m / Total Assets 298.6m)
RoE = -11.56% (Net Income TTM -22.7m / Total Stockholder Equity 196.7m)
RoCE = -11.74% (EBIT -24.8m / Capital Employed (Equity 196.7m + L.T.Debt 14.3m))
RoIC = -9.87% (negative operating profit) (NOPAT -19.6m / Invested Capital 198.2m)
WACC = 10.27% (E(168.6m)/V(186.1m) * Re(10.51%) + D(17.5m)/V(186.1m) * Rd(10.08%) * (1-Tc(0.21)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.97%
[DCF] Fair Price = unknown (Cash Flow -21.3m)
EPS Correlation: 42.25 | EPS CAGR: 18.05% | SUE: 0.73 | # QB: 0
Revenue Correlation: -13.36 | Revenue CAGR: 0.44% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.03 | Chg7d=-0.030 | Chg30d=-0.030 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.52 | Chg7d=-0.360 | Chg30d=-0.360 | Revisions Net=-1 | Growth EPS=-73.3% | Growth Revenue=+5.8%
EPS next Year (2027-12-31): EPS=-0.31 | Chg7d=-0.360 | Chg30d=-0.360 | Revisions Net=-1 | Growth EPS=+40.4% | Growth Revenue=+7.9%